Ilsung Pharmaceuticals Co., Ltd.

KSE 003120.KS

Ilsung Pharmaceuticals Co., Ltd. Free Cash Flow Yield on February 03, 2025: -51.33%

Ilsung Pharmaceuticals Co., Ltd. Free Cash Flow Yield is -51.33% on February 03, 2025, a -75.75% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Ilsung Pharmaceuticals Co., Ltd. 52-week high Free Cash Flow Yield is -29.21% on February 05, 2024, which is 43.10% above the current Free Cash Flow Yield.
Ilsung Pharmaceuticals Co., Ltd. 52-week low Free Cash Flow Yield is -54.20% on January 02, 2025, which is -5.59% below the current Free Cash Flow Yield.
Ilsung Pharmaceuticals Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is -42.68%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

KSE: 003120.KS

Ilsung Pharmaceuticals Co., Ltd.

CEO	Mr. Seok-geun Yoon
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	84-gil 9, Wonhyo-ro
Employees	224
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics

Description

Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, anti-coagulants, circulatory system drugs, contrast agents, diabetes treatments, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years